.. La-présence-fécale-d, IFX est-elle associée à un taux sérique d'IFX plus bas à J1 ou J2 ?, p.99

S. Les and ?. Le-taux-initial-d-'albumine, 104 VII. Discussion, p.105

. Les-caractéristiques-cliniques, biologiques et endoscopiques (scores) ont été exprimées en médianes et valeurs extrêmes (minimum -maximum)

. Dans-le, P. Rutgeerts, W. Sandborn, and B. Feagan, 8) dans le groupe témoin. Nous n'avons pas mis en évidence d'association statistiquement significative entre la présence de SEG et le taux initial d'albumine : p = 0,07. IX. Bibliographie 1 Infliximab for induction and maintenance therapy for ulcerative colitis, N. Engl. J. Med, vol.2419353, pp.6-27, 2005.

W. Sandborn, B. Feagan, and C. Marano, Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.146, issue.1, pp.85-95, 2014.
DOI : 10.1053/j.gastro.2013.05.048

W. Sandborn, G. Assche, . Van, and W. Reinisch, Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.142, issue.2, pp.257-265, 2012.
DOI : 10.1053/j.gastro.2011.10.032

W. Reinisch, W. Sandborn, and D. Hommes, Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial, Gut, vol.60, issue.6, pp.780-787, 2011.
DOI : 10.1136/gut.2010.221127

D. Laharie, A. Bourreille, and J. Branche, Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, The Lancet, vol.380, issue.9857, pp.1909-1924, 2012.
DOI : 10.1016/S0140-6736(12)61084-8

URL : https://hal.archives-ouvertes.fr/hal-00742308

D. Seah, D. Cruz, and P. , Review article: the practical management of acute severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.25, issue.6 Suppl.
DOI : 10.1111/apt.13491

M. Ferrante, S. Vermeire, and K. Katsanos, Predictors of early response to infliximab in patients with ulcerative colitis, Inflammatory Bowel Diseases, vol.13, issue.2, pp.123-128, 2007.
DOI : 10.1002/ibd.20054

D. Gibson, Z. Heetun, and C. Redmond, An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.13, issue.2, pp.330-335, 2015.
DOI : 10.1016/j.cgh.2014.07.041

C. Seow, A. Newman, and S. Irwin, Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis, Gut, vol.59, issue.01, pp.49-54, 2010.
DOI : 10.1136/gut.2009.183095

B. Ungar, I. Levy, Y. Yavne, and M. Yavzori1, Tu1278 Infliximab and Adalimumab Serum Levels Predict Probability of Mucosal Healing, Gastroenterology, vol.148, issue.4, p.846, 2015.
DOI : 10.1016/S0016-5085(15)32866-3

J. Brandse, G. Van-den-brink, M. Wildenberg, D. Van-der-kleij, T. Rispens et al., Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis, Gastroenterology, vol.149, issue.2, pp.350-355, 2015.
DOI : 10.1053/j.gastro.2015.04.016

B. Lovasz, P. Golovisc, Z. Vegh, and P. Lakatos, New trends in inflammatory bowel disease epidemiology and disease course in Eastern Europe, Digestive and Liver Disease, vol.45, issue.4, pp.269-276, 2013.
DOI : 10.1016/j.dld.2012.08.020

. Gower-rousseau, F. Vasseur, M. Fumery, G. Savoyec, J. Salleron et al., Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD), Digestive and Liver Disease, vol.45, issue.2, pp.89-94
DOI : 10.1016/j.dld.2012.09.005

URL : https://hal.archives-ouvertes.fr/tel-00820631

M. Orholm, K. Fonager, and H. Sorensen, Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease, The American Journal of Gastroenterology, vol.31, issue.11, pp.3236-3244, 1999.
DOI : 10.1111/j.1572-0241.1999.01526.x

R. Chapman, J. Fevery, and A. Kalloo, Diagnosis and management of primary sclerosing cholangitis, Hepatology, vol.44, issue.Suppl. 2, p.660, 2010.
DOI : 10.1002/hep.23294

D. Gaya, R. Russell, E. Nimmo, and J. Satsangi, New genes in inflammatory bowel disease: lessons for complex diseases?, The Lancet, vol.367, issue.9518, pp.1271-84, 2006.
DOI : 10.1016/S0140-6736(06)68345-1

B. Khor, A. Gardet, and R. Xavier, Genetics and pathogenesis of inflammatory bowel disease, Nature, vol.105, issue.7351, pp.307-324, 2011.
DOI : 10.1038/nature10209

H. Sokol, C. Lay, P. Seksik, and G. Tannock, Analysis of bacterial bowel communities of IBD patients: What has it revealed?, Inflammatory Bowel Diseases, vol.14, issue.6, pp.858-67, 2008.
DOI : 10.1002/ibd.20392

URL : https://hal.archives-ouvertes.fr/hal-00652970

C. Manichanh, N. Borruel, F. Casellas, and F. Guarner, The gut microbiota in IBD, Nature Reviews Gastroenterology & Hepatology, vol.252, issue.10, pp.599-608, 2012.
DOI : 10.1038/nrgastro.2012.152

G. Lennon, A. Balfe, and N. Bambury, species in ulcerative colitis, Colorectal Disease, vol.54, issue.5, pp.161-170, 2014.
DOI : 10.1111/codi.12503

B. Calkins, A meta-analysis of the role of smoking in inflammatory bowel disease, Digestive Diseases and Sciences, vol.284, issue.12, pp.1841-54, 1989.
DOI : 10.1007/BF01536701

J. Cosnes, Smoking, Physical Activity, Nutrition and Lifestyle: Environmental Factors and Their Impact on IBD, Digestive Diseases, vol.28, issue.3, pp.411-418, 2010.
DOI : 10.1159/000320395

URL : https://hal.archives-ouvertes.fr/hal-00593814

I. Koutroubakis and I. Vlachonikolis, Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies, The American Journal of Gastroenterology, vol.112, issue.1, pp.171-177, 2000.
DOI : 10.1016/S0002-9270(98)00576-0

R. Andersson, G. Olaison, C. Tysk, and A. Ekbom, Appendectomy and Protection against Ulcerative Colitis, New England Journal of Medicine, vol.344, issue.11, pp.808-822, 2001.
DOI : 10.1056/NEJM200103153441104

J. Hou, B. Abraham, and H. El-serag, Dietary Intake and Risk of Developing Inflammatory Bowel Disease: A Systematic Review of the Literature, The American Journal of Gastroenterology, vol.19, issue.4, pp.563-73, 2011.
DOI : 10.1136/bmj.280.6210.293-a

J. Cornish, E. Tan, C. Simillis, S. Clark, J. Teare et al., The Risk of Oral Contraceptives in the Etiology of Inflammatory Bowel Disease: A Meta-Analysis, The American Journal of Gastroenterology, vol.316, issue.6 Suppl, pp.2394-400, 2008.
DOI : 10.1111/j.1572-0241.2008.02064.x

R. Maunder, Evidence that Stress Contributes to Inflammatory Bowel Disease: Evaluation, Synthesis, and Future Directions, Inflammatory Bowel Diseases, vol.11, issue.6, pp.600-608, 2005.
DOI : 10.1097/01.MIB.0000161919.42878.a0

E. Lerebours, C. Gower-rousseau, and M. V. , Stressful Life Events as a Risk Factor for Inflammatory Bowel Disease Onset: A Population-Based Case?Control Study, The American Journal of Gastroenterology, vol.136, issue.1, pp.122-153, 2007.
DOI : 10.1136/jech.55.10.716

L. Chen, L. Egan, Z. Li, F. Greten, M. Kagnoff et al., The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion

M. Leppkes, C. Becker, and I. Ivanov, ROR??-Expressing Th17 Cells Induce Murine Chronic Intestinal Inflammation via Redundant Effects of IL-17A and IL-17F, Gastroenterology, vol.136, issue.1, pp.257-67, 2009.
DOI : 10.1053/j.gastro.2008.10.018

R. Atreya, J. Mudter, and S. Finotto, Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo, Nature Medicine, vol.16, issue.11, pp.583-591, 2000.
DOI : 10.1038/nm1110-1341

F. Carbonnel, A. Lavergne, M. Lemann, A. Bitoun, P. Valleur et al., Colonoscopy of acute colitis, Digestive Diseases and Sciences, vol.21, issue.suppl, pp.1550-1557, 1994.
DOI : 10.1007/BF02088063

X. Treton and D. Laharie, Prise en charge d???une colite aigu?? grave, Gastroent??rologie Clinique et Biologique, vol.32, issue.12, pp.1030-1037, 2008.
DOI : 10.1016/j.gcb.2008.10.005

A. Dignass, R. Eliakim, and F. Magro, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis, Journal of Crohn's and Colitis, vol.6, issue.10, pp.965-90, 2012.
DOI : 10.1016/j.crohns.2012.09.003

E. Langholz, P. Munkholm, M. Davidsen, and V. Binder, Course of ulcerative colitis: Analysis of changes in disease activity over years, Gastroenterology, vol.107, issue.1, pp.3-11, 1994.
DOI : 10.1016/0016-5085(94)90054-X

S. Shah, J. Colombel, B. Sands, and N. Narula, Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis, Clinical Gastroenterology and Hepatology, vol.14, issue.9, 2016.
DOI : 10.1016/j.cgh.2016.01.015

D. Palli, G. Trallori, O. Tarantino, E. Edili, D. et al., General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence study, Gut, vol.42, issue.2, pp.175-184, 1998.
DOI : 10.1136/gut.42.2.175

R. Goebes, . Riddellb, . Östc, . Jensfeltd, and . Perssond, A reproducible grading scale for histological assessment of inflammation in ulcerative colitis, Gut, vol.47, issue.3, pp.404-409, 2000.
DOI : 10.1136/gut.47.3.404

L. Dinesen, A. Walsh, and M. Protic, The pattern and outcome of acute severe colitis, Journal of Crohn's and Colitis, vol.4, issue.4, pp.431-438, 2010.
DOI : 10.1016/j.crohns.2010.02.001

S. Roberts, J. Williams, and D. Yeates, Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies, BMJ, vol.335, issue.7628, p.1033, 2007.
DOI : 10.1136/bmj.39345.714039.55

D. Haens, G. Sandborn, W. J. Feagan, B. G. Geboes, K. Hanauer et al., A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis, Gastroenterology, vol.132, pp.763-786, 2007.

M. Harbord, V. Annese, and R. Stephan, The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. ECCO guidelines, Journal of Crohn's and Colitis, pp.239-254, 2016.

V. Annese, M. Daperno, and D. Matthew, European evidence based consensus for endoscopy in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.7, issue.12, pp.982-1018, 2013.
DOI : 10.1016/j.crohns.2013.09.016

S. P. Travis, D. Schnell, and P. Krzeski, Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Gut, vol.61, issue.4, pp.535-542, 2012.
DOI : 10.1136/gutjnl-2011-300486

A. Dignass, J. Lindsay, and A. Sturm, Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management, Journal of Crohn's and Colitis, vol.6, issue.10, pp.991-1030, 2012.
DOI : 10.1016/j.crohns.2012.09.002

J. Tang, O. Sharif, C. Pai, and A. Silverman, Mesalamine Protects Against Colorectal Cancer in Inflammatory Bowel Disease, Digestive Diseases and Sciences, vol.23, issue.11 Pt1, pp.1696-703, 2010.
DOI : 10.1007/s10620-009-0942-x

G. Nguyen, A. Gulamhusein, and C. Bernstein, 5-Aminosalicylic Acid Is Not Protective Against Colorectal Cancer in Inflammatory Bowel Disease: A Meta-Analysis of Non-Referral Populations, The American Journal of Gastroenterology, vol.107, issue.9, pp.1298-130, 2012.
DOI : 10.1053/j.gastro.2010.02.007

J. Marshall, M. Thabane, A. Steinhart, J. Newman, A. Anand et al., Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.11, p.4118, 2012.

B. Feagan and J. Macdonald, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
DOI : 10.1002/14651858.CD000543.pub3

B. Feagan and J. Macdonald, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
DOI : 10.1002/14651858.CD000544.pub3

N. Khan, A. Abbas, Y. Koleva, and L. Bazzano, Long-Term Mesalamine Maintenance in Ulcerative Colitis, Inflammatory Bowel Diseases, vol.19, issue.6, pp.1123-1132, 2013.
DOI : 10.1097/MIB.0b013e318280b1b8

S. Ardizzone, G. Maconi, A. Russo, V. Imbesi, E. Colombo et al., Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, vol.55, issue.1, pp.47-53, 2006.
DOI : 10.1136/gut.2005.068809

A. Timmer, J. Mcdonald, D. Tsoulis, and J. Macdonald, Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.478, 2012.

R. Panaccione, S. Ghosh, and S. Middleton, Infliximab, azathioprine or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis. The UC SUCCESS trial, J Crohns Colitis, vol.5, p.13, 2011.

G. Vernier-massouille, J. Cosnes, and M. Lemann, Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine, Gut, vol.56, issue.10, pp.1404-1413, 2007.
DOI : 10.1136/gut.2006.114363

URL : https://hal.archives-ouvertes.fr/hal-00815835

J. Rahier, S. Ben-horin, and Y. Chowers, European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease, Journal of Crohn's and Colitis, vol.3, issue.2, pp.47-91, 2009.
DOI : 10.1016/j.crohns.2009.02.010

U. Kandiel, A. Fraser, A. Korelitz, B. Brensinger, C. Lewis et al., Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, vol.54, issue.8, pp.1121-1126, 2005.
DOI : 10.1136/gut.2004.049460

L. Peyrin-biroulet, K. Khosrotehrani, and F. Carrat, Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease, Gastroenterology, vol.141, issue.5, pp.1621-1628, 2011.
DOI : 10.1053/j.gastro.2011.06.050

URL : https://hal.archives-ouvertes.fr/hal-00631539

R. Oren, N. Arber, S. Odes, M. Moshkowitz, D. Keter et al., Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial, Gastroenterology, vol.110, issue.5, pp.1416-1437, 1996.
DOI : 10.1053/gast.1996.v110.pm8613046

F. Carbonnel, J. Colombel, and J. Filippi, Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative??Colitis, Gastroenterology, vol.150, issue.2, pp.380-388, 2016.
DOI : 10.1053/j.gastro.2015.10.050

URL : https://hal.archives-ouvertes.fr/hal-01303796

S. Lichtiger, D. Present, and A. Kornbluth, Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994.
DOI : 10.1056/NEJM199406303302601

D. Haens, G. Lemmens, L. Geboes, K. Vandeputte, L. Van et al., Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis, Gastroenterology, vol.120, issue.6, pp.1323-1329, 2001.
DOI : 10.1053/gast.2001.23983

D. N. Moskovitz, A. G. Van, B. Maenhout, J. Arts, M. Ferrante et al., Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.4, issue.6, pp.760-765, 2006.
DOI : 10.1016/j.cgh.2006.04.001

B. Feagan, P. Rutgeerts, B. Sands, S. Hanauer, J. Colombel et al., Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.369, issue.8, pp.699-710, 2013.
DOI : 10.1056/NEJMoa1215734

. Øreslandt, W. Bemelman, and G. Sampietro, On behalf of the European Crohn's and Colitis Organisation (ECCO) European, Evidence based consensus on surgery for ulcerative colitis, Journal of Crohn's and Colitis, pp.4-25, 2015.

F. J. Fleming, T. D. Francone, M. J. Kim, D. Gunzler, S. Messing et al., A Laparoscopic Approach Does Reduce Short-Term Complications in Patients Undergoing Ileal Pouch-Anal Anastomosis, Diseases of the Colon & Rectum, vol.54, issue.2, pp.176-182, 2011.
DOI : 10.1007/DCR.0b013e3181fb4232

S. A. Bartels, A. D-'hoore, M. A. Cuesta, A. J. Bensdorp, C. Lucas et al., Significantly Increased Pregnancy Rates After Laparoscopic Restorative Proctocolectomy, Annals of Surgery, vol.256, issue.6, pp.1045-1048, 2012.
DOI : 10.1097/SLA.0b013e318250caa9

J. Randall, B. Singh, B. Warren, S. Travis, N. Mortensen et al., Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications, British Journal of Surgery, vol.44, issue.3, pp.404-409, 2010.
DOI : 10.1002/bjs.6874

D. Salmon-ceron, F. Tubach, O. Lortholary, O. Chosidow, S. Bretagne et al., Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry, Annals of the Rheumatic Diseases, vol.70, issue.4, pp.616-639, 2011.
DOI : 10.1136/ard.2010.137422

URL : https://hal.archives-ouvertes.fr/hal-00875446

H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos et al., O07 LONG-TERM SAFETY OF INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER COHORT STUDY, Journal of Crohn's and Colitis Supplements, vol.1, issue.1, pp.501-509, 2009.
DOI : 10.1016/S1873-9954(07)70009-5

T. Felekis, K. Katsanos, D. Christodoulou, I. Asproudis, and E. Tsianos, Reversible bilateral optic neuritis after Infliximab discontinuation in a patient with Crohn's disease, Journal of Crohn's and Colitis, vol.3, issue.3, pp.212-216, 2009.
DOI : 10.1016/j.crohns.2009.04.001

G. Lichtenstein, B. Feagan, and R. Cohen, Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT??? Registry, The American Journal of Gastroenterology, vol.31, issue.9, pp.1409-1431, 2012.
DOI : 10.3899/jrheum.100347

M. Long, C. Martin, C. Pipkin, H. Herfarth, R. Sandler et al., Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel Disease, Gastroenterology, vol.143, issue.2, pp.390-399, 2012.
DOI : 10.1053/j.gastro.2012.05.004

N. Vande-casteele, D. Buurman, M. Sturkenboom, J. Kleibeuker, S. Vermeire et al., Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays, Alimentary Pharmacology & Therapeutics, vol.35, issue.8, pp.765-71, 2012.
DOI : 10.1111/apt.12030

W. Afif, E. Loftus, J. Faubion, W. Kane, S. Bruining et al., Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease, The American Journal of Gastroenterology, vol.26, issue.5, pp.1133-1142, 2010.
DOI : 10.1053/j.gastro.2006.11.041

S. Paul, D. Tedesco, E. Marotte, and H. , Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.19, issue.12, pp.2568-76, 2013.
DOI : 10.1097/MIB.0b013e3182a77b41

B. Ungar, Y. Chowers, and M. Yavzori, The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab, Gut, vol.18, issue.(Suppl 1), pp.1258-64, 2014.
DOI : 10.1136/gutjnl-2013-305259

V. Casteele and N. , Individualised infliximab regimen using therapeutic drug monitoring: a prospective controlled trough level adapted infliximab treatment trial (TAXIT), UEGW 2013. J. of Crohn's and Colitis

B. Ungar, Y. Mazor, and R. Weisshof, Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis, Alimentary Pharmacology & Therapeutics, vol.11, issue.12, pp.1293-1299, 2016.
DOI : 10.1111/apt.13631

A. Yarur, A. Jain, and A. Sussman, The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study, Gut, vol.46, issue.(Suppl 6), pp.249-255, 2016.
DOI : 10.1136/gutjnl-2014-308099